POLATUZUMAB VEDOTIN

Information current as at:

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Polivy®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
ROCHE PRODUCTS PTY LTD
Condition/indication:
(therapeutic use)
  • Diffuse large B-cell lymphoma (DLBCL)
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New PBS listing (Standard Re-entry Pathway)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
March 2025 PBAC meeting
Opportunity for consumer comment:
Open 27/11/2024 and close 29/01/2025 (see PBS Website)
PBAC meeting:
Held on 12/03/2025
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – March 2025
Case ID
a1016
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19